Cogent Biosciences, Inc.

COGT Healthcare Biotechnology

In the quarter to June 2026, EPS grew 1.89% and free cash flow fell 42.0%, each against the same quarter a year earlier.

29.52 0.01 +0.03%
Market cap
$5.1B
P/E
0.0×
Fwd P/E
−5.2×
Dividend yield
—
F-score
3/9
Altman Z
3.55
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
6.38 14.23 15.14 13.57
Net Debt/EBITDA
4.20 6.80 6.19 5.55
Debt/Equity
0.15 0.35 0.37 0.42
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.47) (0.62) (0.54) (0.45)
Book value per Share
2.20 4.94 3.75 3.11
Free Cash Flow
(64.35) (79.92) (87.33) (77.64)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates